한빛사논문
- 조회345
Sohn, Won MD, PhD1,6; Chang, Yoosoo MD, PhD2,3,4,6; Cho, Yong Kyun MD, PhD1,4,7,**; Hong, Yun Soo MD5; Ryu, Seungho MD2,3,4,7,**
1 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
2 Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, South Korea
3 Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, South Korea
4 Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea
5 Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
6 Drs Sohn and Chang contributed equally as co-first authors
7 Drs Ryu and Cho are corresponding authors
**Correspondence
Abstract
Objectives:br /> Whether isolated hepatitis B core antibody (Anti-HBc) positivity is a risk factor for long-term liver-related outcomes in hepatitis B virus (HBV)-endemic areas remains unclear. We aimed to investigate liver-related and liver cancer mortality of isolated anti-HBc positivity in Korean adults.
Design:
A cohort study comprised 609,299 Korean adults who underwent hepatitis B serologic markers, as a part of health examination. Liver-related and liver cancer mortality was determined using the National Death Records.
Results:
During a median follow-up of 9.0 years (interquartile range, 5.5–13.7 years), 554 liver-related deaths were identified (liver-related mortality, 9.6 cases per 105 person-years). The prevalence of isolated anti-HBc positivity was 3.8% (n=23,399) and was age-dependent. After adjustment for age, sex, and other confounders, hazard ratios (95% CI) for liver-related mortality in isolated anti-HBc positive and HBsAg positive subjects compared to HBV-unexposed subjects were 1.69 (1.22–2.33) and 27.02 (21.45–34.04), respectively. These associations were pronounced in the analyses using liver cancer mortality as an outcome. Among isolated anti-HBc positive patients, the risks of liver-related and liver cancer mortality were significantly higher in those with high Fibrosis-4 scores compared with patients unexposed to HBV with the multivariable-adjusted hazard ratios (95% CI) of 15.59 (9.21–26.37) and 72.66 (36.96–142.86), respectively.
Conclusions:
In this cohort of Korean adults, isolated anti-HBc positivity was associated with an increased risk of liver-related and liver cancer mortality, especially when accompanied by a high fibrosis score. Isolated anti-HBc positivity may be an independent risk factor for liver-related outcomes, especially in high-endemic areas.
논문정보
- Research article
- 2022년 09월 (BRIC 등록일 2022-09-15)
- 국내(교신)+국외 연구진
- 의약학 > 응용의학
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
